Oncolytics Biotech Inc.
ONCY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.27 | 0.12 | 0.19 |
| FCF Yield | -3.37% | -5.72% | -9.70% | -7.85% |
| EV / EBITDA | -13.52 | -14.60 | -7.63 | -10.21 |
| Quality | ||||
| ROIC | -177.11% | -42.21% | -49.21% | -61.42% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.46 | 0.89 | 0.97 | 0.98 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -21.70% | 15.80% | 17.24% | -61.43% |
| Safety | ||||
| Net Debt / EBITDA | 0.84 | 2.45 | 2.07 | 1.78 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |